CeyHello, a newly launched social networking mobile app, tackles medication adherence by connecting patients, caregivers and family members.
Omnichannel as company commitment is nothing new to technical marketing in pharma. Marketers now need a broader omnichannel funnel continuously open to deeper customer engagement.
Technology executives discussed how pharma companies can leverage social media to better engage with patients online.
An inVentiv Health study indicates patient groups want more say in drug development and patient support.
The patient journey concept needs a reboot, according to executives at the inaugural MM&M Transforming Healthcare conference.
An upcoming leadership summit is devoted to exploring whether health social media is driving meaningful change, as well as new ways to engage with health activists.
David Schlanger is the company's new chief executive, a role he's filled on an interim basis since May.
Execs told Weber Shandwick that internal hurdles such as insufficient expertise and unclear ROI measures are really what's keeping them from the social-media mix.
A Novartis survey finds many women with advanced breast cancer feel left out by an awareness movement focused on prevention, early detection and pink merchandise.
A new FDA site gives patients a one-stop shop for commenting on pending regulations, finding clinical trials and navigating treatment options.
Executives from big pharma pulled few punches on the opening day of eyeforpharma's Barcelona 2013 conference, lambasting their industry for its failure to adequately serve patients and develop enough innovative products.
MS patients have an "insatiable appetite" for information about treatments online, particularly the new class of oral treatments, whose manufacturers could be doing more to prep them for switch conversations, a survey suggests.
The American Heart Association is trying to get us thinking about using social networks—in both the old-school, interpersonal connections sense as well as the newer electronic one—to tackle childhood obesity.
Pfizer has the strongest social media presence of any pharma, a WEGO Health/Digital Health Coalition poll suggests.
Hearing patient activists and pharma and agency execs talk about connecting through social and other online channels brings to mind a room full of awkward wallflowers at a high school dance.
Health information site HealthCentral has been acquired by Remedy Health, a multimedia provider of content and tools designed to help people manage disease, the firms said today.
WEGO Health is launching an ad-supported online video network, dubbed WEGOHealth.tv, that will feature "conversation-style videos" featuring its medical subject matter expert "health activists."
Specialty pharma companies are launching online hubs tuned to the needs of the orphan community.
GlaxoSmithKline and Human Genome Sciences launched a patient community for lupus sufferers and their friends and family, in anticipation of an FDA decision on Benlysta in March.
Patient advocacy groups are an increasingly valuable resource for pharma manufacturers and FDA throughout the drug development process, since they provide, among other things, a crucial perspective, according to a New York Pharma Forum panel last week.
Social networks are a "Wild West" of medical misinformation, a study has found. More than one in four comments on Facebook diabetes communities is promotional in nature, generally for unapproved products, Harvard and Brigham and Women's Hospital researchers said.
WebMD is launching a social networking platform, dubbed WebMD Health Exchange, aimed at giving users more control and connecting them with experts to talk about health issues in real time.
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Sunovion hires former BI exec as VP of marketing
- Five things for pharma marketers to know: Wednesday, October 19, 2016
- Five things for pharma marketers to know: Monday, October 24, 2016
- Five things for pharma marketers to know: Tuesday, October 25, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy